Download PDF
Semin Neurol 2000; Volume 20(Number 03): 375-386
DOI: 10.1055/s-2000-9429
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Controversies in Neurological Infectious Diseases

John E. Greenlee, John W. Rose
  • Neurology Service, Veterans Affairs Medical Center and Department of Neurology, University of Utah Health Science Center, Salt Lake City, Utah
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

The past several years have seen major advances in our understanding of neurological infectious diseases, their diagnosis, and their treatment. Along with these advances, however, new information about infectious agents and new therapeutic options have also introduced both uncertainty and controversy in the approach and management of patients with diseases of the central nervous system. Here, we discuss six such areas: the long-term efficacy of HAART therapy in treatment of HIV infection; the role of viral infection in chronic fatigue syndrome; Rasmussen's encephalitis as an infectious or autoimmune disease; the spectrum of neurological diseases caused by rickettsial infection; the role of Mycoplasma pneumoniae in human central nervous system disease; and the possible association of Chlamydia pneumoniae and human herpesvirus 6 with multiple sclerosis.

KEYWORD

Rasmussen's encephalitis - chronic fatigue syndrome - rickettsial infection - mycoplasma pneumoniae - multiple sclerosis - controversies in neurology

REFERENCES

  • 1 Hanna G J, Hirsch M S. Antiretroviral therapy of human immunodeficiency virus infection. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed Philadelphia: Churchill-Livingstone; 2000;0:1479-1500
    Google Scholar
  • 2 Palella F J, Delaney K M, Moorman A C. Declining morbidity and mortality among patients with advanced immunodeficiency virus infection.  N Engl J Med . 1998;  338 853-860
    CrossrefPubMedGoogle Scholar
  • 3 Hogg R S, Heath K V, Yip B. Improved survival of HIV infected individuals following initiation of antiretroviral therapy.  JAMA . 1998;  279 450-454
    CrossrefPubMedGoogle Scholar
  • 4 Gendelman H E, Zheng J, Coulter C L. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia.  J Infect Dis . 1998;  178 1000-1007
    PubMedGoogle Scholar
  • 5 Sepkowitz K A. Effect of HAART on natural history of AIDS-related opportunistic disorders.  Lancet . 1998;  351 228-230
    CrossrefPubMedGoogle Scholar
  • 6 Carr A, Marriott D, Field A, Vasak E, Cooper D A. Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.  Lancet . 1998;  351 256-261
    CrossrefPubMedGoogle Scholar
  • 7 Aboulafia D M. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy.  Mayo Clin Proc . 1998;  73 439-443
    PubMedGoogle Scholar
  • 8 Calista D, Boschini A, Landi G. Resolution of disseminated molluscum contagiosum with highly active anti-retroviral therapy (HAART) in patients with AIDS.  Eur J Dermatol . 1999;  9 211-213
    PubMedGoogle Scholar
  • 9 Anders H J, Goebel F D. Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome.  Int J STD AIDS . 1999;  10 151-159
    CrossrefPubMedGoogle Scholar
  • 10 Rauz S, Murray P I. Changing patterns of HIV related ocular disease.  Sex Transm Infect . 1999;  75 18-20
    PubMedGoogle Scholar
  • 11 Albrecht H, Hoffmann C, Degen O. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy.  AIDS . 1998;  12 1149-115
    CrossrefPubMedGoogle Scholar
  • 12 Clifford D B, Yiannoutsos C, Glicksman M. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy [see comments].  Neurology . 1999;  52 623-625
    PubMedGoogle Scholar
  • 13 Miralles P, Berenguer J, Garcia de Viedma D. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy.  AIDS . 1998;  12 2467-2472
    CrossrefPubMedGoogle Scholar
  • 14 Ho D D, Neumann A U, Perelson A S. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.  Nature . 1995;  373 123-126
    CrossrefPubMedGoogle Scholar
  • 15 Wong J K, Hezareh M, Gunthard H F. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.  Science . 1997;  278 1291-1295
    CrossrefPubMedGoogle Scholar
  • 16 Zhang L, Ramratnam B, Tenner Racz K. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy [see comments].  N Engl J Med . 1999;  340 1605-1613
    CrossrefPubMedGoogle Scholar
  • 17 Ledergerber B, Egger M, Opravil M. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.  Lancet . 1999;  353 863-868
    CrossrefPubMedGoogle Scholar
  • 18 Selwyn P A, Arnold R. From fate to tragedy: the changing meanings of life, death, and AIDS.  Ann Intern Med . 1998;  129 899-902
    PubMedGoogle Scholar
  • 19 Michelet C, Arvieux C, Francois C. Opportunistic infections occurring during highly active antiretroviral treatment.  AIDS . 1998;  12 1815-1822
    PubMedGoogle Scholar
  • 20 Cassoux N, Lumbroso L, Bodaghi B, Zazoun L, Katlama C, LeHoang P. Cystoid macular oedema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy.  Br J Ophthalmol . 1999;  83 47-49
    PubMedGoogle Scholar
  • 21 Jacobson M A, Zegans M, Pavan P R. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy [see comments].  Lancet . 1997;  349 1443-1445
    CrossrefPubMedGoogle Scholar
  • 22 De Luca A, Ammassari A, Cingolani A, Giancola M L, Antinori A. Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy [letter].  AIDS . 1998;  12 1937-1938
    PubMedGoogle Scholar
  • 23 Coffin J M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.  Science . 1995;  267 483-489
    PubMedGoogle Scholar
  • 24 d'Arminio Monforte A, Testa L, Adorni F. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.  AIDS . 1998;  12 1631-1637
    CrossrefPubMedGoogle Scholar
  • 25 Vigouroux C, Gharakhanian S, Salhi Y. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.  Diabetes Metab . 1999;  25 383-392
    PubMedGoogle Scholar
  • 26 Tobi R, Morag A, Ravid Z. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection.  Lancet . 1982;  1 61-64
    PubMedGoogle Scholar
  • 27 DuBois R E, Seeley J K, Brus I. Chronic mononucleosis syndrome.  South Med J . 1984;  77 1376-1382
    PubMedGoogle Scholar
  • 28 Jones J F, Ray C G, Minnich L L. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses.  Ann Intern Med . 1985;  105 1-7
    PubMedGoogle Scholar
  • 29 Straus S E, Tosato G, Armstrong G. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection.  Ann Intern Med . 1985;  102 7-16
    PubMedGoogle Scholar
  • 30 Holmes G P, Kaplan J E, Gantz N M. Chronic fatigue syndrome: a working case definition.  Ann Intern Med . 1988;  108 387-389
    PubMedGoogle Scholar
  • 31 Fukuda K, Strauss S E, Hickie I. The chronic fatigue syndrome: a comprehensive approach to its definition and study.  Ann Intern Med . 1994;  121 953-959
    Google Scholar
  • 32 Lloyd I, Hickie I, Peterson P K. Chronic fatigue syndrome. In: Richman DD, Whitley RJ, Hayden FG, eds. Clinical virology New York: Churchill Livingstone 1997: 343-355
    Google Scholar
  • 33 Sairenji T, Yamanishi K, Tachibana Y, Bertoni G, Kurata T. Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome.  Intervirology . 1995;  38 269-273
    PubMedGoogle Scholar
  • 34 Levine P H, Jacobson S, Pocinki A G. Clinical, epidemiologic, and virologic studies in four clusters of the chronic fatigue syndrome [see comments].  Arch Intern Med . 1992;  152 1611-1616
    CrossrefPubMedGoogle Scholar
  • 35 Buchwald D, Ashley R L, Pearlman T, Kith P, Komaroff A L. Viral serologies in patients with chronic fatigue and chronic fatigue syndrome.  J Med Virol . 1996;  50 25-30
    CrossrefPubMedGoogle Scholar
  • 36 White P D, Thomas J M, Amess J. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever.  Br J Psychiatry . 1998;  173 475-481
    CrossrefPubMedGoogle Scholar
  • 37 Read R, Larson E, Harvey J. Clinical and laboratory findings in the Paul-Bunnell negative glandular fever-fatigue syndrome.  J Infect . 1990;  21 157-165
    PubMedGoogle Scholar
  • 38 Smith M S, Mitchell J, Corey L. Chronic fatigue in adolescents [see comments].  Pediatrics . 1991;  88 195-202
    PubMedGoogle Scholar
  • 39 Wallace H L, Natelson B, Gause W, Hay J. Human herpesviruses in chronic fatigue syndrome.  Clin Diagn Lab Immunol . 1999;  6 216-223
    PubMedGoogle Scholar
  • 40 Ablashi D V. Viral studies of chronic fatigue syndrome.  Clin Infect Dis . 1994;  S130-S133 (S130-S133)
    PubMedGoogle Scholar
  • 41 Martin W J, Zeng L C, Ahmed K, Roy M. Cytomegalovirus-related sequence in an atypical cytopathic virus repeatedly isolated from a patient with chronic fatigue syndrome.  Am J Pathol . 1994;  145 440-451
    PubMedGoogle Scholar
  • 42 Martin W J. Simian cytomegalovirus-related stealth virus isolated from the cerebrospinal fluid of a patient with bipolar psychosis and acute encephalopathy.  Pathobiology . 1996;  64 64-66
    PubMedGoogle Scholar
  • 43 Miller G, Carmichael H A, Calder B D. Antibody to Coxsackie B virus in diagnosing postviral fatigue syndrome.  Br Med J . 1988;  302 140-142
    PubMedGoogle Scholar
  • 44 Yousef G E, Bell E J, Mann G F. Chronic enterovirus infection in patients with postviral fatigue syndrome.  Lance . 1988;  1 146-147
    PubMedGoogle Scholar
  • 45 Archard L C, Bowles N E, Behan P O. Postviral fatigue syndrome: Persistence of enterovirus RNA in muscle and elevated creatine kinase.  J R Soc Med . 1988;  81 326-330
    PubMedGoogle Scholar
  • 46 Gow J W, Behan W M, Clements G B, Woodall C, Riding M, Behan P O. Enteroviral RNA sequences detected by polymerase chain reaction in muscle of patients with postviral fatigue syndrome [see comments].  BMJ . 1991;  302 692-696
    CrossrefPubMedGoogle Scholar
  • 47 Galbraith D N, Nairn C, Clements G B. Evidence for enteroviral persistence in humans.  J Gen Virol . 1997;  78 307-312
    PubMedGoogle Scholar
  • 48 Cunningham L, Bowles N E, Lane R J, Dubowitz V, Archard L C. Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA.  J Gen Virol . 1990;  71 1399-1402
    CrossrefPubMedGoogle Scholar
  • 49 Lloyd A R, Hales J P, Gandevia S C. Muscle strength, endurance, and recovery in the post-infection fatigue syndrome.  J Neurol Neurosurg Psychiatry . 1988;  51 1316-1319
    PubMedGoogle Scholar
  • 50 Lloyd A R, Gandevia S C, Hales J P. Muscle endurance, twitch properties, voluntary activation, and perceived exertion in normal subjects and patients with chronic fatigue syndrome.  Brain . 1991;  114 85-93
    PubMedGoogle Scholar
  • 51 Defreitas E, Hilliard B, Cheney P R. Retroviral sequences related to human T-lymphotrophic virus type II in patients with chronic fatigue immune dysfunction syndrome.  Proc Natl Acad Sci U S A . 1991;  88 2922-2925
    PubMedGoogle Scholar
  • 52 Heneine W, Woods T C, Sinha S D. Lack of evidence for infection with known human and animal retroviruses in patients with chronic fatigue syndrome.  Clin Infect Dis . 1994;  S121-S125 (S121-S125)
    PubMedGoogle Scholar
  • 53 Folks T M, Heneine W, Khan A, Woods T, Chapman L, Schonberger L. Investigation of retroviral involvement in chronic fatigue syndrome.  Ciba Found Symp . 1993;  173 160-166
    PubMedGoogle Scholar
  • 54 Gow J W, Simpson K, Schliephake A. Search for retrovirus in the chronic fatigue syndrome.  J Clin Pathol . 1992;  45 1058-1054
    PubMedGoogle Scholar
  • 55 Dale J K, Di Bisceglie A M, Hoofnagle J H, Straus S E. Chronic fatigue syndrome: lack of association with hepatitis C virus infection.  J Med Virol . 1991;  34 119-121
    PubMedGoogle Scholar
  • 56 Nakaya T, Takahashi H, Nakamura Y. Demonstration of Borna disease virus RNA in peripheral blood mononuclear cells derived from Japanese patients with chronic fatigue syndrome.  FEBS Lett . 1996;  378 145-149
    CrossrefPubMedGoogle Scholar
  • 57 Manningham R. The Symptoms, Nature, and Causes of the Febricula or Little Fever: Commonly Called Nervous or Hysteric Fever; the Fever on the Spirits; Vapors, Hypo or Spleen. 2nd ed. London: J Robinson; 1750 . 
    Google Scholar
  • 58 Beard G. Neurasthenia or nervous exhaustion.  Boston Med Surg J (New Ser) . 1869;  3 217-225
    PubMedGoogle Scholar
  • 59 Wheeler E O, White P D, Reed E W, Cohen M E. Neurocirculatory asthenia (anxiety neurosis, effort syndrome, neurasthenia): a twenty year follow-up study of one hundred and seventy three patients.  JAMA . 1950;  142 878-889
    PubMedGoogle Scholar
  • 60 Schrader H, Obelieniene D, Bovim G, Surkiene D, Mickeviciene D, Miseviciene I. Natural evolution of late whiplash outside the medicolegal context.  Lancet . 1996;  347 1207-1211
    CrossrefPubMedGoogle Scholar
  • 61 Farrell M A, DeRosa M J, Curran J G. Neuropathologic findings in cortical resections (including hemispherectomies) performed for the treatment of intractable childhood epilepsy.  Acta Neuropathol (Berl) . 1992;  83 246-259
    CrossrefPubMedGoogle Scholar
  • 62 Friedman H, Chi'en L, Parham D. Virus in brain of child with hemiplegia, hemiconvulsions, and epilepsy.  Lancet . 1977;  2 666
    PubMedGoogle Scholar
  • 63 Walter G F, Renella R R. Epstein-Barr virus in brain and Rasmussen's encephalitis [letter].  Lancet . 1989;  1 279-280
    CrossrefPubMedGoogle Scholar
  • 64 Power C, Poland S D, Blume W T, Girvin J P, Rice G PA. Cytomegalovirus and Rasmussen's encephalitis.  Lancet . 1990;  336 1282-1284
    CrossrefPubMedGoogle Scholar
  • 65 McLachlan R S, Girvin J P, Blume W T, Reichman H. Rasmussen's chronic encephalitis in adults.  Arch Neurol . 1993;  50 269-274
    PubMedGoogle Scholar
  • 66 Jay V, Becker L E, Blaser S. Pathology of chronic herpes infection associated with seizure disorder: a report of two cases with tissue detection of herpes simplex virus 1 by the polymerase chain reaction.  Pediatr Pathol Lab Med . 1995;  15 131-146
    PubMedGoogle Scholar
  • 67 Jay V, Becker L E, Otsubo H. Chronic encephalitis and epilepsy (Rasmussen's encephalitis): detection of cytomegalovirus and herpes simplex virus 1 by the polymerase chain reaction and in situ hybridization.  Neurology . 1995;  45 108-117
    CrossrefPubMedGoogle Scholar
  • 68 Atkins M R, Terrell W, Hulette C M. Rasmussen's syndrome: a study of potential viral etiology.  Clin Neuropathol . 1995;  14 7-12
    PubMedGoogle Scholar
  • 69 Rogers S W, Andrews P I, Gahring L C. Antibodies to glutamate receptor GluR3 in Rasmussen's encephalitis.  Science . 1994;  265 648-653
    CrossrefPubMedGoogle Scholar
  • 70 Krauss G L, Campbell M L, Roche K W, Huganir R L, Niedermeyer E. Chronic steroid-responsive encephalitis without autoantibodies to glutamate receptor GluR3.  Neurology . 1996;  46 247-249
    PubMedGoogle Scholar
  • 71 Andrews P I, McNamara J O, Lewis D V. Clinical and electroencephalographic correlates in Rasmussen's encephalitis.  Epilepsia . 1997;  38 189-194
    PubMedGoogle Scholar
  • 72 Palmer C A, Geyer J D, Keating J M. Rasmussen's encephalitis with concomitant cortical dysplasia: the role of GluR3.  Epilepsia . 1999;  40 242-247
    PubMedGoogle Scholar
  • 73 He X P, Patel M, Whitney K D, Janumpalli S, Tenner A, McNamara J O. Glutamate receptor GluR3 antibodies and death of cortical cells.  Neuron . 1998;  20 153-163
    CrossrefPubMedGoogle Scholar
  • 74 Levite M, Hermelin A. Autoimmunity to the glutamate receptor in mice: a model for Rasmussen's encephalitis?.  J Autoimmun . 1999;  13 73-82
    CrossrefPubMedGoogle Scholar
  • 75 Hart Y M, Cortez M, Andermann F. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients.  Neurology . 1994;  44 1030-1036
    CrossrefPubMedGoogle Scholar
  • 76 Chinchilla D, Dulac O, Robain O. Reappraisal of Rasmussen's syndrome with special emphasis on treatment with high doses of steroids.  J Neurol Neurosurg Psychiatry . 1994;  57 1325-1333
    CrossrefPubMedGoogle Scholar
  • 77 Andrews P I, Dichter M A, Berkovic S F, Newton M R, McNamara J O. Plasmapheresis in Rasmussen's encephalitis [see comments].  Neurology . 1996;  46 242-246
    CrossrefPubMedGoogle Scholar
  • 78 Antozzi C, Granata T, Aurisano N. Long-term selective IgG immuno-adsorption improves Rasmussen's encephalitis.  Neurology . 1998;  51 302-305
    CrossrefPubMedGoogle Scholar
  • 79 Caraballo R, Tenembaum S, Cersosimo R. [Rasmussen syndrome] Sindrome de Rasmussen.  Rev Neurol . 1998;  26 978-983
    PubMedGoogle Scholar
  • 80 Leach J P, Chadwick D W, Miles J B, Hart I K. Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy.  Neurology . 1999;  52 738-742
    PubMedGoogle Scholar
  • 81 McLachlan R S, Levin S, Blume W T. Treatment of Rasmussen's syndrome with ganciclovir.  Neurology . 1996;  47 925-928
    PubMedGoogle Scholar
  • 82 DeToledo J C, Smith D B. Partially successful treatment of Rasmussen's encephalitis with zidovudine: symptomatic improvement followed by involvement of the contralateral hemisphere.  Epilepsia . 1994;  35 352-355
    PubMedGoogle Scholar
  • 83 Dabbagh O, Gascon G, Crowell J, Bamoggadam F. Intraventricular interferon-alpha stops seizures in Rasmussen's encephalitis: a case report.  Epilepsia . 1997;  38 1045-1049
    PubMedGoogle Scholar
  • 84 Maria B L, Ringdahl D M, Mickle J P. Intraventricular alpha interferon therapy for Rasmussen's syndrome.  Can J Neurol Sci . 1993;  20 333-336
    PubMedGoogle Scholar
  • 85 Kim J H, Durack D T. Rickettsiae. In: Scheld WM, Durack DT, Whitley RJ, eds. Infections of the Central Nervous System 2nd ed. Philadelphia: Lippincott-Raven 1997: 403-416
    Google Scholar
  • 86 Miller J Q, Price T R. The nervous system in Rocky Mountain spotted fever.  Neurology . 1972;  22 561-566
    PubMedGoogle Scholar
  • 87 Westerman E L. Rocky mountain spotless fever: a dilemma for the clinician.  Arch Intern Med . 1982;  142 1106-1107
    CrossrefPubMedGoogle Scholar
  • 88 Pai H, Sohn S, Seong Y, Kee S, Chang W H, Choe K W. Central nervous system involvement in patients with scrub typhus.  Clin Infect Dis . 1997;  24 436-440
    CrossrefPubMedGoogle Scholar
  • 89 Garg P, Blass D A. Rocky Mountain spotted fever manifested by cerebritis and pneumonitis.  Md Med J . 1987;  36 343-345
    PubMedGoogle Scholar
  • 90 Paddock C D, Greer P W, Ferebee T L. Hidden mortality attributable to Rocky Mountain spotted fever: immunohistochemical detection of fatal, serologically unconfirmed disease.  J Infect Dis . 1999;  179 1469-1476
    CrossrefPubMedGoogle Scholar
  • 91 Wei T Y, Baumann R J. Acute disseminated encephalomyelitis after Rocky Mountain spotted fever.  Pediatr Neurol . 1999;  21 503-505
    CrossrefPubMedGoogle Scholar
  • 92 Duma R J, Sonenshine D E, Bozeman F M. Epidemic typhus in the United States associated with flying squirrels.  JAMA . 1981;  245 2318-2323
    CrossrefPubMedGoogle Scholar
  • 93 Ratnasamy N, Everett E D, Roland W E, McDonald G, Caldwell C W. Central nervous system manifestations of human ehrlichiosis.  Clin Infect Dis . 1996;  23 314-319
    PubMedGoogle Scholar
  • 94 Winslow G M, Yager E, Shilo K, Collins D N, Chu F K. Infection of the laboratory mouse with the intracellular pathogen Ehrlichia chaffeensis Infect Immun .  1998;  66 3892-3899
    PubMedGoogle Scholar
  • 95 Grant A C, Hunter S, Partin W C. A case of acute monocytic ehrlichiosis with prominent neurologic signs.  Neurology . 1997;  48 1619-1623
    PubMedGoogle Scholar
  • 96 Dunn B E, Monson T P, Dumler J S. Identification of Ehrlichia chaffeensis morulae in cerebrospinal fluid mononuclear cells.  J Clin Microbiol . 1992;  30 2207-2210
    PubMedGoogle Scholar
  • 97 Carter N, Miller N R. Fourth nerve palsy caused by Ehrlichia chaffeensis J Neuroophthalmol .  1997;  17 47-50
    PubMedGoogle Scholar
  • 98 Carpenter C F, Gandhi T K, Kong L K. The incidence of ehrlichial and rickettsial infection in patients with unexplained fever and recent history of tick bite in central North Carolina.  J Infect Dis . 1999;  180 900-903
    CrossrefPubMedGoogle Scholar
  • 99 Wenzel R P, Hayden F G, Groschel D H. Acute febrile cerebrovasculitis: a syndrome of unknown, perhaps rickettsial, cause.  Ann Intern Med . 1986;  104 606-615
    PubMedGoogle Scholar
  • 100 Hechemy K E, Fox J A, Groschel D H, Hayden F G, Wenzel R P. Immunoblot studies to analyze antibody to the Rickettsia typhi group antigen in sera from patients with acute febrile cerebrovasculitis.  J Clin Microbiol . 1991;  29 2559-2565
    PubMedGoogle Scholar
  • 101 Linnemann Jr C C, Pretzman C I, Peterson E D. Acute febrile cerebrovasculitis: a non-spotted fever group rickettsial disease.  Arch Intern Med . 1989;  149 1682-1684
    CrossrefPubMedGoogle Scholar
  • 102 Campbell T A, Strong P S, Grier G S. Primary atypical pneumoniae: two hundred cases at Ft. Eustin, Va.  JAMA . 1943;  122 723-729
    PubMedGoogle Scholar
  • 103 Clyde Jr WA. Mycoplasmal diseases. In: Scheld WM, Durack DT, Whitley RJ, eds. Infections of the Central Nervous System 2nd ed. Philadelphia: Lippincott-Raven 1997: 603-612
    Google Scholar
  • 104 Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review.  Clin Infect Dis . 1993;  S52-S57 (S52-S57)
    PubMedGoogle Scholar
  • 105 Thomas N H, Collins J E, Robb S A, Robinson R O. Mycoplasma pneumoniae infection and neurological disease [see comments].  Arch Dis Child . 1993;  69 573-576
    Google Scholar
  • 106 Kolski H, Ford Jones E L, Richardson S. Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995.  Clin Infect Dis . 1998;  26 398-409
    CrossrefPubMedGoogle Scholar
  • 107 Heckmann J G, Sommer J B, Druschky A, Erbguth F J, Steck A J, Neundorfer B. Acute motor axonal neuropathy associated with IgM anti-GM1 following Mycoplasma pneumoniae infection.  Eur Neurol . 1999;  41 175-176
    CrossrefPubMedGoogle Scholar
  • 108 Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection.  Muscle Nerve . 1995;  18 409-413
    PubMedGoogle Scholar
  • 109 Kasahara I, Otsubo Y, Yanase T, Oshima H, Ichimaru H, Nakamura M. Isolation and characterization of Mycoplasma pneumoniae from cerebrospinal fluid of a patient with pneumonia and meningoencephalitis.  J Infect Dis . 1985;  152 823-825
    PubMedGoogle Scholar
  • 110 Abramovitz P, Schvartzmann P, Harel D, Lis I, Naot Y. Direct invasion of the central nervous system by Mycoplasma pneumoniae: a report of two cases.  J Infect Dis . 1987;  155 482-487
    PubMedGoogle Scholar
  • 111 Cano Sanchez A, Cano Gracia H, Fernandez Pardo J, Artero Galan J M, Gonzalez Sicilia L. Aseptic meningitis caused by Mycoplasma pneumoniae in a 19-year-old woman.  Eur J Clin Microbiol Infect Dis . 1999;  18 228-229
    CrossrefPubMedGoogle Scholar
  • 112 Ieven M, Demey H, Ursi D, Van Goethem G, Cras P, Goossens H. Fatal encephalitis caused by Mycoplasma pneumoniae diagnosed by the polymerase chain reaction.  Clin Infect Dis . 1998;  27 1552-1553
    PubMedGoogle Scholar
  • 113 Agard C, Hamidou M, Gires C, Grolleau J Y, Raffi F. [Polynuclear neutrophils meningitis disclosing Mycoplasma pneumoniae infection (letter)] Meningite a polynucleaires neutrophiles revelant une infection a Mycoplasma pneumoniae Rev Med Interne .  1996;  17 1043-1044
    PubMedGoogle Scholar
  • 114 Fisher R S, Clark A W, Wolinsky J S, Parhad I M, Moses H, Mardiney M R. Postinfectious leukoencephalitis complicating Mycoplasma pneumoniae infection.  Arch Neurol . 1983;  40 113
    PubMedGoogle Scholar
  • 115 Pellegrini M, O'Brien T J, Hoy J, Sedal L. Mycoplasma pneumoniae infection associated with an acute brainstem syndrome.  Acta Neurol Scand . 1996;  93 203-206
    PubMedGoogle Scholar
  • 116 Nadkarni N, Lisak R P. Guillain-Barré syndrome (GBS) with bilateral optic neuritis and central white matter disease.  Neurology . 1993;  43 842-843.
    PubMedGoogle Scholar
  • 117 Kikuchi M, Tagawa Y, Iwamoto H, Hoshino H, Yuki N. Bickerstaff's brainstem encephalitis associated with IgG anti-GQ1b antibody subsequent to Mycoplasma pneumoniae infection: favorable response to immunoadsorption therapy.  J Child Neurol . 1997;  12 403-405
    CrossrefPubMedGoogle Scholar
  • 118 Westenfelder G O, Akey D T, Corwin S J, Vick N A. Acute transverse myelitis due to Mycoplasma pneumoniae infection.  Arch Neurol . 1981;  38 317
    PubMedGoogle Scholar
  • 119 Saitoh S, Wada T, Narita M. Mycoplasma pneumoniae infection may cause striatal lesions leading to acute neurologic dysfunction.  Neurology . 1993;  43 2150-2151
    PubMedGoogle Scholar
  • 120 Al-Mateen M, Gibbs M, Dietrich R, Mitchell W G, Menkes J H. Encephalitis lethargica-like illness in a girl with mycoplasma infection.  Neurology . 1988;  38 1155-1158
    PubMedGoogle Scholar
  • 121 Feder H M, Watkin T, Cole S R, Quintiliani R. Severe meningoencephalitis complicating Mycoplasma pneumoniae infection in a child.  Arch Pathol Lab Med . 1981;  105 619-621
    PubMedGoogle Scholar
  • 122 Fernandez C V, Bortolussi R, Gordon K, Lee S H, Gatien J G, Shahdrabadi M S. Mycoplasma pneumoniae infection associated with central nervous system complications.  J Child Neurol . 1993;  8 27-31.
    PubMedGoogle Scholar
  • 122a Narita M, Matsuzono Y, Togashi T. DNA diagnosis of central nervous system infection by Mycoplasma pneumoniae.  Pediatrics . 1992;  90 250-253
    PubMedGoogle Scholar
  • 123 Dorff B, Lind K. Two fatal cases of meningoencephalitis associated with Mycoplasma pneumoniae infection.  Scand J Infect Dis . 1976;  8 49-51
    PubMedGoogle Scholar
  • 124 Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS.  Neurology . 1998;  50 571-572
    PubMedGoogle Scholar
  • 125 Sriram S, Stratton C, Yao S. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis.  Ann Neurol . 1999;  46 4-5
    CrossrefPubMedGoogle Scholar
  • 126 Trieb J, Haass A, Stille W. Multiple sclerosis and Chlamydia pneumoniae Ann Neurol .  2000;  47 408
    PubMedGoogle Scholar
  • 127 Perlmutter L, Darvish M. Possible relationship of Chlamydia pneumoniae to multiple sclerosis.  Med Hypotheses . 1983;  12 95-98
    PubMedGoogle Scholar
  • 128 Le Gac P, Wulffaert F, Arquie E. The psittacosis virus in the etiology of multiple sclerosis.  C R Acad Sci Hebd Seances Acad Sci D . 1966;  22 1793-1795
    PubMedGoogle Scholar
  • 129 Hoption Cann S, van Netten J, van Netten C. Chlamydia, Rickettsia and antibiotic treatment of multiple sclerosis.  Ann Neurol . 2000;  47 408-409
    PubMedGoogle Scholar
  • 130 Sriam S, Stratton C, Yao S. (Reply to letter).  Ann Neurol . 2000;  47 409-411
    CrossrefPubMedGoogle Scholar
  • 131 Meinl E. Concepts of viral pathogenesis of multiple sclerosis.  Curr Opin Neurol . 1999;  12 303-307
    CrossrefPubMedGoogle Scholar
  • 132 Dockrell D, Smith T, Paya C. Human herpesvirus 6.  Mayo Clin Proc . 1999;  74 163-170
    PubMedGoogle Scholar
  • 133 Albright A, Lavi E, Black J. The effect of human herpesvirus-6 (HHV-6) on cultured human neural cells: oligodendrocytes and microglia.  J Neurovirol . 1998;  5 486-494
    PubMedGoogle Scholar
  • 134 Soldan S, Leist T, Juhng K. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients.  Ann Neurol . 2000;  47 306-313
    CrossrefPubMedGoogle Scholar
  • 135 Santoro F, Kennedy P, Locatelli G. CD46 is a cellular receptor for human herpesvirus 6.  Cell . 1999;  99 817-827
    CrossrefPubMedGoogle Scholar
  • 136 Torelli G, Barozzi P, Marasca R. Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of peripheral blood lymphocytes.  J Med Virol . 1995;  46 178-188
    PubMedGoogle Scholar
  • 137 Sola P, Merelli E, Marasca R. Human herpesvirus-6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and viral sequences by polymerase chain reaction.  J Neurol Neurosurg Psychiatry . 1993;  56 917-919
    PubMedGoogle Scholar
  • 138 Soldan S, Berti R, Salem N. Association of herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.  Nat Med . 1997;  12 1394-1397
    PubMedGoogle Scholar
  • 139 Ongradi J, Rajda C, Maordi C. A pilot study on the antibodies to HHV-6 variants and HHV-7 in CSF of MS patients.  J Neurovirol . 1999;  5 529-532
    PubMedGoogle Scholar
  • 140 Wilborn F, Schmidt C, Brinkmann V. A potential role for human herpesvirus type 6 in nervous system disease.  J Neuroimmunol . 1994;  49 213-214
    CrossrefPubMedGoogle Scholar
  • 141 Ablashi D, Lapps W, Kaplan M. Human herpes virus-6 (HHV-6) infection in multiple sclerosis: preliminary report.  Multiple Sclerosis . 1998;  4 490-496
    CrossrefPubMedGoogle Scholar
  • 142 Goldberg S, Albright A, Lisak R. Polymerase chain reaction analysis of human herpesvirus-6 sequences in the sera and cerebrospinal fluid of patients with multiple sclerosis.  J Neurovirol . 1995;  5 134-139
    PubMedGoogle Scholar
  • 143 Enbom M, Wang F, Fredickson S. Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls.  Clin Diagn Lab Immunol . 1999;  6 545-549
    PubMedGoogle Scholar
  • 144 Mirandola P, Stefan A, Brambilla E. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients.  Neurology . 1999;  53 1367-1368
    PubMedGoogle Scholar
  • 145 Mayne M, Kishnan J, Metz L. Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients.  Ann Neurol . 1998;  44 391-394
    CrossrefPubMedGoogle Scholar
  • 146 Merille E, Bedin R, Sola P. Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults and children.  J Neurol . 1997;  244 450-454
    PubMedGoogle Scholar
  • 147 Martin C, Enbom M, Soderstrom M. Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis.  Acta Neurol Scand . 1997;  95 280-283
    PubMedGoogle Scholar
  • 148 Nielsen L, Lasen A, Munk M. Human herpesvirus-6 immunoglobulin G antibodies in patients with multiple sclerosis.  Acta Neurol Scand Suppl . 1997;  169 76-78
    PubMedGoogle Scholar
  • 149 Soldan S, Berti R, Secchiero P. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.  Nat Med . 1997;  3 1394-1397
    CrossrefPubMedGoogle Scholar
  • 150 Challoner P, Smith K, Parker J. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis.  Proc Natl Acad Sci U S A . 1995;  92 7440-7444
    PubMedGoogle Scholar
  • 151 Sanders V J, Felisan S, Waddell A. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction.  J Neurovirol . 1996;  2 249-258
    CrossrefPubMedGoogle Scholar
  • 152 Mock D, Powers C, Goodman A. Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy.  J Neurovirol . 1999;  5 363-373
    PubMedGoogle Scholar
  • 153 Merelli E, Sola P, Barozzi P, Torelli G. An encephalitic episode in a multiple sclerosis patient with human herpesvirus 6 latent infection.  J Neurol Sci . 1996;  137 42-46
    CrossrefPubMedGoogle Scholar
  • 154 Carrigan D, Harrington D, Knox K. Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis.  Neurology . 1996;  47 145-148
    PubMedGoogle Scholar
  • 155 Novoa L, Nagra R, Nakwatase T. Fulminant demyelinating encephalomyelitis associated with productive HHV-6 infection in an immunocompetent adult.  J Med Virol . 1997;  52 301-308
    CrossrefPubMedGoogle Scholar
  • 156 Liedke W, Malessa R, Faustmann P. Human herpesvirus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis.  J Neurovirol . 1995;  1 253-258
    PubMedGoogle Scholar
  • 157 Rotola A, Cassai E, Tola M. Human herpesvirus 6 is latent in peripheral blood of patients with relapsing-remitting multiple sclerosis.  J Neurol Neurosurg Psychiatry . 1999;  67 529-531
    PubMedGoogle Scholar
  • 158 Monteyne P, Bureau J, Brahic M. Viruses and multiple sclerosis.  Curr Opin Neurol . 1998;  11 287-291
    PubMedGoogle Scholar
  • 159 Johnson R T. Virology of demyelinating diseases.  Ann Neurol . 1994;  36 S54-S60
    CrossrefPubMedGoogle Scholar
  • 160 Blumberg B, Mock D, Powers J. The HHV-6 paradox: ubiquitous commensal or insidious pathogen?.  <~>A two step in situ PCR approach. J Clin Virol . 2000;  16 159-178
    PubMedGoogle Scholar
      >